The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 08, 2020
Filed:
Feb. 23, 2015
Applicants:
National Cancer Center, Chuo-ku, Tokyo, JP;
Daiichi Sankyo Company, Limited, Chuo-ku, Tokyo, JP;
Inventors:
Takashi Kohno, Chuo-ku, JP;
Hideaki Ogiwara, Chuo-ku, JP;
Yuichi Tominaga, Shinagawa-ku, JP;
Saito Higuchi, Shinagawa-ku, JP;
Assignees:
National Cancer Center, Chuo-ku, Tokyo, JP;
Daiichi Sankyo Company, Limited, Chuo-ku, Tokyo, JP;
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4155 (2006.01); G01N 33/574 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); C12Q 1/68 (2018.01); C12N 15/09 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57484 (2013.01); A61K 31/4155 (2013.01); C12N 15/09 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6886 (2013.01); G01N 33/50 (2013.01); G01N 33/574 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/47 (2013.01); G01N 2333/91057 (2013.01); G01N 2500/10 (2013.01); G01N 2800/52 (2013.01);
Abstract
It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.